SGLT2 inhibition $\hat{a} \in$ "a novel strategy for diabetes treat

Nature Reviews Drug Discovery 9, 551-559 DOI: 10.1038/nrd3180

Citation Report

#	Article	IF	CITATIONS
1	Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. Diabetes Therapy, 2010, 1, 45-56.	2.5	28
2	Discovery of Non-Glycoside Sodium-Dependent Glucose Co-Transporter 2 (SGLT2) Inhibitors by Ligand-Based Virtual Screening. Journal of Medicinal Chemistry, 2010, 53, 8770-8774.	6.4	27
3	A survey of small molecule glucagon receptor antagonists from recent patents (2006 – 2010). Expert Opinion on Therapeutic Patents, 2011, 21, 1211-1240.	5.0	26
4	EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats. Pharmacological Research, 2011, 63, 284-293.	7.1	57
5	Le rein, un nouvel organe cible des hypoglycémiants. Medecine Des Maladies Metaboliques, 2011, 5, S37-S41.	0.1	1
6	Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors. Journal of Medicinal Chemistry, 2011, 54, 2952-2960.	6.4	112
7	Management of type 2 diabetes: new and future developments in treatment. Lancet, The, 2011, 378, 182-197.	13.7	459
8	Kidney in Diabetes: from Organ Damage Target to Therapeutic Target. Current Drug Metabolism, 2011, 12, 658-666.	1.2	13
9	Novel treatments for type 2 diabetes. British Journal of General Practice, 2011, 61, 5-6.	1.4	8
11	Antibodies in metabolic diseases. New Biotechnology, 2011, 28, 530-537.	4.4	14
12	The Approach to Model Building. , 2011, , 43-68.		0
13	One pot protecting group free synthesis of multifunctional biphenyl methyl-C-β-d-glycosides in aqueous medium. Tetrahedron, 2011, 67, 740-748.	1.9	23
14	Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Therapy, 2011, 2, 133-145.	2.5	52
15	A New Approach to Glucose Control in Type 2 Diabetes: The Role of Kidney Sodium-Glucose Co-transporter 2 Inhibition. Postgraduate Medicine, 2011, 123, 38-45.	2.0	12
16	SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic Î ² -Cell Function. Diabetes, 2011, 60, 890-898.	0.6	197
17	Structural Insights into the Active Site of Human Sodium Dependent Glucose Co-Transporter 2: Homology Modelling, Molecular Docking, and 3D - QSAR Studies. Australian Journal of Chemistry, 2012, 65, 1314.	0.9	20
18	Targeting Renal Glucose Reabsorption for the Treatment of Type 2 Diabetes Mellitus Using the SGLT2 Inhibitor Dapagliflozin. Postgraduate Medicine, 2012, 124, 62-73.	2.0	12
19	New antidiabetic therapies. Current Opinion in Lipidology, 2012, 23, 569-575.	2.7	17

	Сітат	ion Report	
#	ARTICLE LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a	IF	CITATIONS
20	Randomized, Placebo-Controlled Trial. Clinical Pharmacology and Therapeutics, 2012, 92, 158-169.	4.7	221
21	Hypoglycemic Potential of Current and Emerging Pharmacotherapies in Type 2 Diabetes Mellitus. Postgraduate Medicine, 2012, 124, 74-83.	2.0	19
22	The Role of the Kidney and Sodium-Clucose Cotransporter-2 Inhibition in Diabetes Management. Clinical Diabetes, 2012, 30, 151-155.	2.2	16
23	Sugar Absorption. , 2012, , 1583-1593.		10
24	Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2012, 5, 135.	2.4	51
25	The Kidney as a Treatment Target for Type 2 Diabetes. Diabetes Spectrum, 2012, 25, 29-36.	1.0	6
26	Structural selectivity of human SGLT inhibitors. American Journal of Physiology - Cell Physiology, 2012, 302, C373-C382.	4.6	71
27	Development of a cell-based nonradioactive glucose uptake assay system for SGLT1 and SGLT2. Analytical Biochemistry, 2012, 429, 70-75.	2.4	42
28	A novel SGLT is expressed in the human kidney. European Journal of Pharmacology, 2012, 690, 77-83.	3.5	25
29	SGLT2 inhibitors race to enter type-2 diabetes market. Nature Biotechnology, 2012, 30, 899-900.	17.5	18
30	Discovery of Tofogliflozin, a Novel <i>C</i> -Arylglucoside with an <i>O</i> -Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes. Journal of Medicinal Chemistry, 2012, 55, 7828-7840.	6.4	145
31	Stereoselective C-Glycosylation Reactions with Arylzinc Reagents. Organic Letters, 2012, 14, 1480-1483.	4.6	108
32	A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Annals of Medicine, 2012, 44, 375-393.	3.8	247
33	Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Current Medical Research and Opinion, 2012, 28, 1167-1171.	1.9	65
34	Oleanolic Acid Reduces Hyperglycemia beyond Treatment Period with Akt/FoxO1-Induced Suppression of Hepatic Gluconeogenesis in Type-2 Diabetic Mice. PLoS ONE, 2012, 7, e42115.	2.5	56
35	Emerging Therapeutic Targets in Regenerative Medicine for the Treatment of Diabetes Mellitus: A Patent Literature Review. Recent Patents on Regenerative Medicine, 2012, 3, 56-62.	0.4	0
36	Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes. Core Evidence, 2012, 7, 21.	4.7	10
37	Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes. Pharmacological Reviews, 2012, 64, 188-237.	16.0	81

#	Article	IF	CITATIONS
38	Familial renal glucosuria: a clinicogenetic study of 23 additional cases. Pediatric Nephrology, 2012, 27, 1091-1095.	1.7	26
39	Chances and risks of SGLT2 inhibitors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, 385, 551-554.	3.0	5
40	A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Journal of Molecular Modeling, 2012, 18, 2795-2804.	1.8	9
41	Renal distal tubule proliferation and increased aquaporin 2 level but decreased urine osmolality in db/db mouse: Treatment with chromium picolinate. Experimental and Molecular Pathology, 2012, 92, 54-58.	2.1	11
42	Empagliflozin, a novel potent and selective SGLTâ€2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocinâ€induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, 2012, 14, 601-607.	4.4	62
43	Sodium dependent glucose transporter (SGLT) 1 / 2 - elucidating inhibitor SAR and selectivity using homology modelling and 3D QSAR studies. Journal of Cheminformatics, 2012, 4, .	6.1	Ο
44	Atom-based 3D QSAR studies on novel N-β-d-xylosylindole derivatives as SGLT2 inhibitors. Medicinal Chemistry Research, 2013, 22, 615-624.	2.4	9
45	On the importance of synthetic organic chemistry in drug discovery: reflections on the discovery of antidiabetic agent ertugliflozin. MedChemComm, 2013, 4, 101-111.	3.4	29
46	Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes. Diabetes Therapy, 2013, 4, 41-49.	2.5	17
47	Newer anti-hyperglycemic agents in type 2 diabetes mellitus – Expanding the horizon. Apollo Medicine, 2013, 10, 108-112.	0.0	3
48	Antidiabetic agents: past, present and future. Future Medicinal Chemistry, 2013, 5, 411-430.	2.3	31
49	Complementing Insulin Therapy to Achieve Glycemic Control. Advances in Therapy, 2013, 30, 557-576.	2.9	30
50	The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors. Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 350-359.	1.5	26
51	C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 5561-5572.	3.0	25
52	A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant Intravenous Microdose Administration of [13C]Tofogliflozin in Humans. Clinical Pharmacokinetics, 2013, 52, 463-473.	3.5	38
53	Diabetic nephropathy: diagnosis and treatment. Nature Reviews Endocrinology, 2013, 9, 713-723.	9.6	220
54	The efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials. Systematic Reviews, 2013, 2, 103.	5.3	5
55	Regional distribution of SGLT activity in rat brain in vivo. American Journal of Physiology - Cell Physiology, 2013, 304, C240-C247.	4.6	85

#	Article	IF	CITATIONS
56	Aquaporin 11 insufficiency modulates kidney susceptibility to oxidative stress. American Journal of Physiology - Renal Physiology, 2013, 304, F1295-F1307.	2.7	42
57	Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase <scp>II</scp> multicentre, randomized, doubleâ€blind, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2013, 15, 432-440.	4.4	124
58	The Concise Guide to <scp>PHARMACOLOGY</scp> 2013/14: Transporters. British Journal of Pharmacology, 2013, 170, 1706-1796.	5.4	121
59	Design and Synthesis of Diazatricyclodecane Agonists of the G-Protein-Coupled Receptor 119. Journal of Medicinal Chemistry, 2013, 56, 301-319.	6.4	28
60	Glucose transport families SLC5 and SLC50. Molecular Aspects of Medicine, 2013, 34, 183-196.	6.4	222
61	Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a doseâ€finding study. Diabetes, Obesity and Metabolism, 2013, 15, 403-409.	4.4	103
62	Synthesis and antioxidant activity of a novel class of fluorescein-based β-C-glycosides. Carbohydrate Research, 2013, 379, 38-42.	2.3	8
63	Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes, Obesity and Metabolism, 2013, 15, 280-283.	4.4	49
64	Solute carriers as drug targets: Current use, clinical trials and prospective. Molecular Aspects of Medicine, 2013, 34, 702-710.	6.4	89
65	Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opinion on Investigational Drugs, 2013, 22, 463-486.	4.1	71
66	SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. Journal of Pharmacy and Pharmacology, 2013, 65, 317-327.	2.4	32
67	Glucose Reabsorption in The Kidney. , 2013, , 2393-2404.		4
68	Isolation and in silico evaluation of antidiabetic molecules of Cynodon dactylon (L.). Journal of Molecular Graphics and Modelling, 2013, 39, 87-97.	2.4	35
70	SGLT inhibitors: a novel target for diabetes. Pharmaceutical Patent Analyst, 2013, 2, 77-91.	1.1	20
71	CoMFA and CoMSIA studies on <i>C</i> -aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents. SAR and QSAR in Environmental Research, 2013, 24, 519-551.	2.2	23
72	Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. European Journal of Pharmacology, 2013, 715, 246-255.	3.5	248
73	Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes. Clinical Therapeutics, 2013, 35, 273-285.e7.	2.5	71
74	Design, Syntheses, and SAR Studies of Carbocyclic Analogues of Sergliflozin as Potent Sodiumâ€Dependent Glucose Cotransporter 2 Inhibitors. Angewandte Chemie - International Edition, 2013, 52, 8401-8405.	13.8	13

#	Article	IF	CITATIONS
75	Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG. Molecular BioSystems, 2013, 9, 2010.	2.9	17
76	The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Type 2 Diabetes Mellitus. Pharmacotherapy, 2013, 33, 984-999.	2.6	76
77	Protective Effects of Dietary 1,5-Anhydro-d-glucitol as a Blood Glucose Regulator in Diabetes and Metabolic Syndrome. Journal of Agricultural and Food Chemistry, 2013, 61, 611-617.	5.2	14
78	Nonclinical Toxicology Assessments Support the Chronic Safety of Dapagliflozin, a First-in-Class Sodium-Glucose Cotransporter 2 Inhibitor. International Journal of Toxicology, 2013, 32, 336-350.	1.2	32
79	Canagliflozin, a Novel SGLT2 Inhibitor for Treatment of Type 2 Diabetes. Annals of Pharmacotherapy, 2013, 47, 1301-1311.	1.9	23
80	Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor. Endocrine Research, 2013, 38, 168-183.	1.2	4
81	Improved glycemic control in mice lacking Sglt1 and Sglt2. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E117-E130.	3.5	130
82	The Molecular Mechanism of Ion-Dependent Gating in Secondary Transporters. PLoS Computational Biology, 2013, 9, e1003296.	3.2	64
83	Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition. Indian Journal of Endocrinology and Metabolism, 2013, 17, 588.	0.4	28
84	The Role of the Kidney in Hyperglycemia. Journal of Cardiovascular Nursing, 2013, 28, 157-165.	1.1	9
85	Renal Glucose Handling. Diabetes Care, 2013, 36, 1260-1265.	8.6	70
86	Clinical and genetic analysis in a patient with primary renal glucosuria: Identification of a novel mutation in the SLC5A2 gene. Experimental and Therapeutic Medicine, 2013, 6, 1532-1534.	1.8	11
87	Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. Journal of Clinical Pharmacology, 2013, 53, 1028-1038.	2.0	24
88	Tofogliflozin, a novel sodium–glucose coâ€ŧransporter 2 inhibitor, improves renal and pancreatic function in <i>db/db</i> mice. British Journal of Pharmacology, 2013, 170, 519-531.	5.4	78
89	A <scp>P</scp> hase <scp>IIb</scp> , randomized, placebo ontrolled study of the <scp>SGLT2</scp> inhibitor empagliflozin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2013, 15, 721-728.	4.4	162
90	Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E414-E423.	3.5	36
91	Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Doseâ€Dependent Glucosuria in Healthy Subjects. Clinical Pharmacology in Drug Development, 2013, 2, 152-161.	1.6	101
92	Enzymatic Synthesis of Novel Phloretin Glucosides. Applied and Environmental Microbiology, 2013, 79, 3516-3521.	3.1	81

#	Article	IF	CITATIONS
94	Canagliflozin: a novel treatment option for type 2 diabetes. Drug Design, Development and Therapy, 2013, 7, 1399.	4.3	19
96	SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013, 6, 453.	2.4	58
97	Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis. , 0, , .		3
98	Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin. Patient Preference and Adherence, 2014, 8, 493.	1.8	7
99	Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice. PLoS ONE, 2014, 9, e100777.	2.5	271
100	Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes. PLoS ONE, 2014, 9, e105638.	2.5	53
101	Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Design, Development and Therapy, 2014, 8, 1335.	4.3	279
102	Dapagliflozin for the treatment of type 2 diabetes: a review of the literature. Drug Design, Development and Therapy, 2014, 8, 2493.	4.3	21
103	Mammalian Sugar Transporters. , 0, , .		8
104	Asymmetric Synthesis of <i>cis</i> ―and <i>trans</i> â€2â€Arylâ€6â€methylpyrans from <scp>D</scp> â€Gluce Arylation and Inversion of Configuration at the Câ€2 Position. European Journal of Organic Chemistry, 2014, 2014, 244-253.	ose by 2.4	2
105	Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutrition and Diabetes, 2014, 4, e143-e143.	3.2	84
106	Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, for the Management of Type 2 Diabetes. Hospital Practice (1995), 2014, 42, 96-108.	1.0	6
107	Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans. Frontiers in Pharmacology, 2014, 5, 274.	3.5	38
108	Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys. American Journal of Physiology - Renal Physiology, 2014, 306, F1520-F1533.	2.7	13
109	The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials. BMJ Open, 2014, 4, e004619.	1.9	63
110	Ramping Glucosuria for Management of Type 2 Diabetes Mellitus: An Emerging Cynosure. Medicinal Research Reviews, 2014, 34, 1146-1167.	10.5	9
111	A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor. Diabetes and Metabolism Journal, 2014, 38, 261.	4.7	66
112	Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study. Diabetes Therapy, 2014, 5, 415-433.	2.5	56

#	Article	IF	CITATIONS
113	Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients with Type 2 Diabetes. Postgraduate Medicine, 2014, 126, 33-48.	2.0	40
114	Nonclinical Safety of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin. International Journal of Toxicology, 2014, 33, 436-449.	1.2	24
115	Myocardial Steatosis and Necrosis in Atria and Ventricles of Rats Given Pyruvate Dehydrogenase Kinase Inhibitors. Toxicologic Pathology, 2014, 42, 1250-1266.	1.8	8
116	Beneficial effects of phlorizin on diabetic nephropathy in diabetic db/db mice. Journal of Diabetes and Its Complications, 2014, 28, 596-603.	2.3	32
117	Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1,2,3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1528-1531.	2.2	13
119	Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. Journal of the American Society of Hypertension, 2014, 8, 262-275.e9.	2.3	371
120	Industrial natural product chemistry for drug discovery and development. Natural Product Reports, 2014, 31, 35-60.	10.3	210
121	Synthesis of empagliflozin, a novel and selective sodiumâ€glucose coâ€ŧransporterâ€2 inhibitor, labeled with carbonâ€14 and carbonâ€13. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 687-694.	1.0	14
122	Efficient Synthesis of Empagliflozin, an Inhibitor of SGLT-2, Utilizing an AlCl ₃ -Promoted Silane Reduction of a β-Glycopyranoside. Organic Letters, 2014, 16, 4090-4093.	4.6	82
123	Gymnemic Acids Inhibit Sodium-Dependent Glucose Transporter 1. Journal of Agricultural and Food Chemistry, 2014, 62, 5925-5931.	5.2	23
124	Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Diabetes Care, 2014, 37, 740-750.	8.6	234
125	Synthesis of <scp>l</scp> -rhamnose derived chiral bicyclic triazoles as novel sodium-glucose transporter (SGLT) inhibitors. Organic and Biomolecular Chemistry, 2014, 12, 8415-8421.	2.8	8
126	Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin. Chemico-Biological Interactions, 2014, 224, 1-12.	4.0	41
127	Case History. Annual Reports in Medicinal Chemistry, 2014, , 363-382.	0.9	5
128	Novel approaches to drug discovery for the treatment of type 2 diabetes. Expert Opinion on Drug Discovery, 2014, 9, 1047-1058.	5.0	45
129	Canada Welcomes a Novel Class of Oral Glucose-Lowering Drugs for People withÂType 2 Diabetes. Canadian Journal of Diabetes, 2014, 38, 219-220.	0.8	2
130	Natural product and natural product derived drugs in clinical trials. Natural Product Reports, 2014, 31, 1612-1661.	10.3	471
131	Design, Synthesis, and Biological Evaluation of Deuterated <i>C</i> -Aryl Glycoside as a Potent and Long-Acting Renal Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes. Journal of Medicinal Chemistry, 2014, 57, 1236-1251.	6.4	56

#	Article	IF	CITATIONS
132	Blood Pressure and Cardiovascular Effects of New and Emerging Antidiabetic Agents. Current Hypertension Reports, 2014, 16, 455.	3.5	6
133	Clinical implication of SGLT2 inhibitors in type 2 diabetes. Archives of Pharmacal Research, 2014, 37, 957-966.	6.3	19
134	Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovascular Diabetology, 2014, 13, 65.	6.8	168
135	Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. Journal of Pharmacy and Pharmacology, 2014, 66, 975-987.	2.4	100
136	LP â€925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT 1 and SGLT 2. Pharmacology Research and Perspectives, 2015, 3, e00129.	2.4	11
137	Canagliflozin: a sodium glucose coâ€transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Annals of the New York Academy of Sciences, 2015, 1358, 28-43.	3.8	75
138	Flozins, inhibitors of type 2 renal sodium-glucose co-transporter – not only antihyperglycemic drugs. Current Issues in Pharmacy and Medical Sciences, 2015, 28, 155-158.	0.4	3
140	Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease. Journal of Hypertension, 2015, 33, 2185-2197.	0.5	60
141	Design, Synthesis and <i>inÂvivo</i> Evaluation of Novel <i>C</i> â€Aryl Glucosides as Potent Sodiumâ€Dependent Glucose Cotransporters Inhibitors for the Treatment of Diabetes. Chemical Biology and Drug Design, 2015, 86, 764-775.	3.2	3
142	Probing the Catalytic Promiscuity of a Regio―and Stereospecific Câ€Glycosyltransferase from <i>Mangifera indica</i> . Angewandte Chemie - International Edition, 2015, 54, 12678-12682.	13.8	96
143	Design, Synthesis, and Biological Evaluation of Novel Peptide Gly ³ â€< scp>MC62 Analogues as Potential Antidiabetic Agents. Chemical Biology and Drug Design, 2015, 86, 979-989.	3.2	2
144	Canagliflozin-induced pancreatitis: a rare side effect of a new drug. Therapeutics and Clinical Risk Management, 2015, 11, 991.	2.0	27
145	Antidiabetic Drugs: Mechanisms of Action and Potential Outcomes on Cellular Metabolism. Current Pharmaceutical Design, 2015, 21, 3606-3620.	1.9	60
146	Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options. Therapeutics and Clinical Risk Management, 2015, 11, 621.	2.0	33
147	Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice. PLoS ONE, 2015, 10, e0130605.	2.5	93
148	Lipid Effects and Cardiovascular Disease Risk Associated with Glucose-Lowering Medications. Current Cardiology Reports, 2015, 17, 608.	2.9	2
149	QSAR studies on triazole derivatives as sglt inhibitors via CoMFA and CoMSIA. Journal of Molecular Structure, 2015, 1098, 199-205.	3.6	19
150	Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovascular Diabetology, 2015, 14, 142.	6.8	68

#	Article	IF	CITATIONS
151	Transporter-mediated tissue targeting of therapeutic molecules in drug discovery. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 993-997.	2.2	14
153	Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. European Journal of Pharmacology, 2015, 754, 19-24.	3.5	93
154	Dapagliflozin: A new sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. American Journal of Health-System Pharmacy, 2015, 72, 361-372.	1.0	26
155	Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment. Drug Metabolism and Disposition, 2015, 43, 1077-1083.	3.3	12
156	Biotransformation of phloretin by amylosucrase yields three novel dihydrochalcone glucosides. Journal of Biotechnology, 2015, 211, 103-106.	3.8	26
157	Metallothionein deficiency aggravates depleted uranium-induced nephrotoxicity. Toxicology and Applied Pharmacology, 2015, 287, 306-315.	2.8	22
158	Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. American Journal of Physiology - Renal Physiology, 2015, 308, G946-G954.	3.4	83
159	Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes. Clinical Diabetes, 2015, 33, 5-13.	2.2	5
162	Doseâ€ranging efficacy and safety study of ertugliflozin, a sodiumâ€glucose coâ€transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes, Obesity and Metabolism, 2015, 17, 591-598.	4.4	60
163	Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences. Diabetes and Vascular Disease Research, 2015, 12, 78-89.	2.0	298
164	A selectivity study of sodium-dependent glucose cotransporter 2/sodium-dependent glucose cotransporter 1 inhibitors by molecular modeling. Journal of Molecular Recognition, 2015, 28, 467-479.	2.1	15
165	Natural Products for the Treatment of Type 2 Diabetes Mellitus. Planta Medica, 2015, 81, 975-994.	1.3	339
166	Canagliflozin for the treatment of adults with Type 2 diabetes. Diabetes Management, 2015, 5, 183-201.	0.5	9
167	Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Current Medical Research and Opinion, 2015, 31, 1993-2000.	1.9	10
168	Biocompatible polymeric nanocomplexes as an intracellular stimuli-sensitive prodrug for type-2 diabetes combination therapy. Biomaterials, 2015, 73, 149-159.	11.4	26
169	Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. Journal of Diabetes and Its Complications, 2015, 29, 1295-1303.	2.3	115
170	Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. Journal of Clinical and Experimental Hepatology, 2015, 5, 190-198.	0.9	68
171	A novel and selective sodiumâ€glucose cotransporterâ€2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2015, 17, 984-993.	4.4	62

#	Article	IF	CITATIONS
172	α-C-Glycosides via syn Opening of 1,2-Anhydro Sugars with Organozinc Compounds in Toluene/n-Dibutyl Ether. Journal of Organic Chemistry, 2015, 80, 9328-9335.	3.2	16
173	Empagliflozin/Linagliptin: A Review in TypeÂ2 Diabetes. Drugs, 2015, 75, 1547-1557.	10.9	13
174	Organo-zinc Promoted Diastereoselective C-Arylation of 1,2-Anhydrosugars from Arylboronic Acids. Organic Letters, 2015, 17, 4624-4627.	4.6	29
175	SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L1027-L1036.	2.9	75
176	Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study. Diabetes Care, 2015, 38, 355-364.	8.6	197
177	<i>C</i> â€Aryl Glucosides with Substituents at the Distal Aryl Ring as Sodiumâ€Dependent Glucose Cotransporter Inhibitors for the Treatment of Diabetes Mellitus. Chemical Biology and Drug Design, 2015, 86, 246-253.	3.2	8
178	Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy. Diabetes Care, 2015, 38, 431-438.	8.6	66
179	Economic Evaluation of Canagliflozin versus Glimepiride and Sitagliptin in Dual Therapy with Metformin for the Treatment of Type 2 Diabetes in Italy. Global & Regional Health Technology Assessment, 2016, 3, GRHTA.5000229.	0.1	2
180	Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse. Frontiers in Cardiovascular Medicine, 2016, 3, 43.	2.4	93
181	<scp>GLUT</scp> , <scp>SGLT</scp> , and <scp>SWEET</scp> : Structural and mechanistic investigations of the glucose transporters. Protein Science, 2016, 25, 546-558.	7.6	198
182	Enzymatic Synthesis of Acylphloroglucinol 3â€ <i>C</i> â€Clucosides from 2â€ <i>O</i> â€Clucosides using a <i>C</i> â€Clycosyltransferase from <i>Mangifera indica</i> . Chemistry - A European Journal, 2016, 22, 5873-5877.	3.3	23
183	Sodium–glucose coâ€ŧransporter 2 inhibitors: a review of their use in older people with type 2 diabetes mellitus. Journal of Pharmacy Practice and Research, 2016, 46, 377-383.	0.8	3
184	Design, synthesis, structure–activity relationships, and docking studies of pyrazole-containing derivatives as a novel series of potent glucagon receptor antagonists. Bioorganic and Medicinal Chemistry, 2016, 24, 2852-2863.	3.0	13
185	NUEVOS FÃRMACOS EN DIABETES MELLITUS. Revista Médica ClÃnica Las Condes, 2016, 27, 235-256.	0.2	4
186	Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice. Endocrinology, 2016, 157, 1029-1042.	2.8	116
187	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Therapeutic Advances in Endocrinology and Metabolism, 2016, 7, 69-83.	3.2	82
188	Low-carbohydrate diet combined with SGLT2 inhibitor for refractory hyperglycemia caused by insulin antibodies. Diabetes Research and Clinical Practice, 2016, 116, 43-45.	2.8	2
189	Inhibitor Discovery for the Human GLUT1 from Homology Modeling and Virtual Screening. ACS Chemical Biology, 2016, 11, 1908-1916.	3.4	49

#	Article	IF	CITATIONS
190	Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. European Heart Journal, 2016, 37, 3192-3200.	2.2	142
191	Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes. Diabetes Therapy, 2016, 7, 659-678.	2.5	6
192	Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats. American Journal of the Medical Sciences, 2016, 352, 517-523.	1.1	37
193	Palladiumâ€Catalyzed Arylation of Carbasugars Enables the Discovery of Potent and Selective SGLT2 Inhibitors. Angewandte Chemie, 2016, 128, 14022-14025.	2.0	0
194	Palladium atalyzed Arylation of Carbasugars Enables the Discovery of Potent and Selective SGLT2 Inhibitors. Angewandte Chemie - International Edition, 2016, 55, 13818-13821.	13.8	8
195	Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health. Current Osteoporosis Reports, 2016, 14, 345-350.	3.6	19
196	An efficient method for synthesis of bexagliflozin and its carbon-13 labeled analogue. Tetrahedron Letters, 2016, 57, 4684-4687.	1.4	7
197	Thyroid hormone treatment decreases hepatic glucose production and renal reabsorption of glucose in alloxan-induced diabetic Wistar rats. Physiological Reports, 2016, 4, e12961.	1.7	15
198	Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. Nature Reviews Drug Discovery, 2016, 15, 786-804.	46.4	254
199	Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1367-1380.	3.3	4
200	SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies. Endocrine Journal, 2016, 63, 187-191.	1.6	11
201	Synthesis, Photophysical, Electrochemical Studies, and Antioxidant Properties of Fluoresceinâ€Linked Glycodendrimers. Asian Journal of Organic Chemistry, 2016, 5, 1155-1163.	2.7	12
202	Stereoselective and Regioselective Preparation of <i>C</i> â€Pentopyranosides and Formal Synthesis of Omarigliptin. European Journal of Organic Chemistry, 2016, 2016, 5624-5628.	2.4	3
203	Baseline low-density lipoprotein cholesterol predicts the hemoglobin A1c-lowering effect of dapagliflozin in Japanese patients with type 2 diabetes mellitus. Diabetology International, 2016, 7, 77-82.	1.4	0
204	Sodium–glucose cotransporter 2 inhibition: cardioprotection by treating diabetes—a translational viewpoint explaining its potential salutary effects. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 244-255.	3.0	38
205	Forxiga (dapagliflozin): Plausible role in the treatment of diabetesâ€associated neurological disorders. Biotechnology and Applied Biochemistry, 2016, 63, 145-150.	3.1	46
206	Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-NaA¬ve Type 2 Diabetes. Diabetes Care, 2016, 39, 353-362.	8.6	105
207	Changes in Type 2 Diabetes Mellitus Patients in German Primary Care Prior to (2006) and After (2010,) Tj ETQq1	1 0.78431	14 rgBT /Ove

#	Article	IF	Citations
208	Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats. Life Sciences, 2016, 147, 125-131.	4.3	43
209	Better results from prevention than from additional treatment. Nature Reviews Cardiology, 2016, 13, 75-77.	13.7	2
210	Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice. Biochemical and Biophysical Research Communications, 2016, 470, 772-782.	2.1	56
211	Effects of diabetes drugs on the skeleton. Bone, 2016, 82, 93-100.	2.9	130
212	Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy. Journal of Diabetes, 2017, 9, 248-255.	1.8	3
213	Pharmacological aspects of the safety of gliflozins. Pharmacological Research, 2017, 118, 71-81.	7.1	55
215	Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radical Biology and Medicine, 2017, 104, 298-310.	2.9	330
216	Clinical parameters affecting dapagliflozin response in patients with type 2 diabetes. Diabetes and Metabolism, 2017, 43, 191-194.	2.9	9
217	Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 249-253.	1.9	45
218	SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 700-710.	4.5	171
219	Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy, 2017, 18, 517-527.	1.8	5
220	Mizagliflozin, a novel selective SCLT1 inhibitor, exhibits potential in the amelioration of chronic constipation. European Journal of Pharmacology, 2017, 806, 25-31.	3.5	29
221	Phosphate imbalance in patients with heart failure. Heart Failure Reviews, 2017, 22, 349-356.	3.9	17
222	Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician. International Journal of Clinical Practice, 2017, 71, e12937.	1.7	22
223	Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: clinical implication of the importance of exercise habits during treatment with ipragliflozin. Diabetology International, 2017, 8, 275-285.	1.4	10
224	Do effects of sodium–glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?. Current Opinion in Nephrology and Hypertension, 2017, 26, 358-367.	2.0	27
225	Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates. Current Medical Research and Opinion, 2017, 33, 1155-1163.	1.9	4
226	Proximal Tubulopathy: Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease. Diabetes, 2017, 66, 791-800.	0.6	231

#	Article	IF	CITATIONS
227	Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?. Digestive and Liver Disease, 2017, 49, 235-240.	0.9	35
228	Gene expression signature: a powerful approach for drug discovery in diabetes. Journal of Endocrinology, 2017, 232, R131-R139.	2.6	9
229	Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes. Clinical Diabetes, 2017, 35, 141-153.	2.2	1
230	SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicology and Applied Pharmacology, 2017, 333, 43-50.	2.8	170
231	Recent Advances in the Chemical Synthesis of <i>C</i> -Glycosides. Chemical Reviews, 2017, 117, 12281-12356.	47.7	398
232	Protective effects of phloridzin against methotrexate-induced liver toxicity in rats. Biomedicine and Pharmacotherapy, 2017, 95, 529-535.	5.6	60
233	Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis. Scientific Reports, 2017, 7, 11906.	3.3	13
234	Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhibition. Scientific Reports, 2017, 7, 5581.	3.3	11
235	SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia, 2017, 60, 1862-1872.	6.3	134
236	Coumarins as potential antidiabetic agents. Journal of Pharmacy and Pharmacology, 2017, 69, 1253-1264.	2.4	121
238	Leaving the Glucocentric View. Journal of the American College of Cardiology, 2017, 70, 713-714.	2.8	0
239	Renal glucose metabolism in normal physiological conditions and in diabetes. Diabetes Research and Clinical Practice, 2017, 133, 1-9.	2.8	112
240	A Predominant Oxidative Renal Metabolite of Empagliflozin in Male Mice Is Cytotoxic in Mouse Renal Tubular Cells but not Genotoxic. International Journal of Toxicology, 2017, 36, 440-448.	1.2	11
241	Glycosyl Cross-Coupling of Anomeric Nucleophiles: Scope, Mechanism, and Applications in the Synthesis of Aryl <i>C</i> -Glycosides. Journal of the American Chemical Society, 2017, 139, 17908-17922.	13.7	96
242	Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity. American Journal of Physiology - Renal Physiology, 2017, 313, F951-F954.	2.7	17
243	Chemical constituents and pharmacological actions of carob pods and leaves (Ceratonia siliqua L.) on the gastrointestinal tract: A review. Biomedicine and Pharmacotherapy, 2017, 93, 522-528.	5.6	77
244	Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials. International Journal of Cardiology, 2017, 228, 352-358.	1.7	59
245	Non-insulin anti-diabetic drugs: An update on pharmacological interactions. Pharmacological Research, 2017, 115, 14-24.	7.1	19

#	Article	IF	CITATIONS
246	Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview. Advances in Therapy, 2017, 34, 41-59.	2.9	20
247	Beneficial effects of sodium–glucose cotransporter 2 inhibitors for preservation of pancreatic β â€cell function and reduction of insulin resistance. Journal of Diabetes, 2017, 9, 219-225.	1.8	51
248	Clinical inertia to insulin initiation and intensification in the UK: A focused literature review. Primary Care Diabetes, 2017, 11, 3-12.	1.8	170
249	<i>Ceratonia siliqua</i> L. (immature carob bean) inhibits intestinal glucose absorption, improves glucose tolerance and protects against alloxanâ€induced diabetes in rat. Journal of the Science of Food and Agriculture, 2017, 97, 2664-2670.	3.5	33
250	Vascular failure and recent anti-diabetic drugs. Vascular Failure, 2017, 1, 2-8.	0.2	3
251	Long-Term Effects of Ipragliflozin on Adipose Tissue in Japanese Patients with Obese Type 2 Diabetes. Journal of Obesity & Weight Loss Therapy, 2017, 07, .	0.1	0
252	Orthostatic Intolerance in Older Persons: Etiology and Countermeasures. Frontiers in Physiology, 2017, 8, 803.	2.8	57
253	Characteristics and Impact Factors of Renal Threshold for Glucose Excretion in Patients with Type 2 Diabetes Mellitus. Journal of Korean Medical Science, 2017, 32, 621.	2.5	14
254	Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 317-332.	2.4	11
256	Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Design, Development and Therapy, 2017, Volume 11, 2905-2919.	4.3	67
257	Biocatalytic C-Glucosylation of Coumarins Using an Engineered C-Glycosyltransferase. Organic Letters, 2018, 20, 1634-1637.	4.6	25
258	Insight into the interaction mechanism of human SGLT2 with its inhibitors: 3D-QSAR studies, homology modeling, and molecular docking and molecular dynamics simulations. Journal of Molecular Modeling, 2018, 24, 86.	1.8	11
259	SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. Primary Care Diabetes, 2018, 12, 265-283.	1.8	62
260	Discovery of thiopheneâ€containing biaryl amide derivatives as novel glucagon receptor antagonists. Chemical Biology and Drug Design, 2018, 92, 1241-1254.	3.2	2
261	The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). Hormones, 2018, 17, 219-229.	1.9	37
262	Is the management of diabetes different in dialysis patients?. Seminars in Dialysis, 2018, 31, 367-376.	1.3	6
263	Production of acetophenone C-glucosides using an engineered C-glycosyltransferase in Escherichia coli. Tetrahedron Letters, 2018, 59, 1875-1878.	1.4	7
264	Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect. Cell Death and Disease, 2018, 9, 226.	6.3	58

#	Article	IF	CITATIONS
265	A Phase 1, Randomized, Placebo―and Activeâ€Controlled Crossover Study to Determine the Effect of Singleâ€Dose Ertugliflozin on QTc Interval in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2018, 7, 513-523.	1.6	15
266	Longâ€ŧerm efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes, Obesity and Metabolism, 2018, 20, 1453-1460.	4.4	70
267	The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data. Hormones, 2018, 17, 83-95.	1.9	3
268	Anti-Diabetic Drugs: Cure or Risk Factors for Cancer?. Pathology and Oncology Research, 2018, 24, 745-755.	1.9	16
269	SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and metaâ \in analysis. Diabetes, Obesity and Metabolism, 2018, 20, 1977-1982.	4.4	53
270	Sodiumâ€glucose coâ€transporter typeâ€2 inhibitors: pharmacology and periâ€operative considerations. Anaesthesia, 2018, 73, 1008-1018.	3.8	50
271	Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment. Diabetes Research and Clinical Practice, 2018, 135, 178-184.	2.8	34
272	Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2. European Journal of Medicinal Chemistry, 2018, 143, 611-620.	5.5	13
273	Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. International Journal of Cancer, 2018, 142, 1712-1722.	5.1	136
274	Effects of the sodiumâ€glucose cotransporter 2 (<scp>SGLT</scp> 2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. Journal of Veterinary Pharmacology and Therapeutics, 2018, 41, 266-273.	1.3	10
275	Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution. European Journal of Pharmacology, 2018, 818, 545-553.	3.5	7
276	Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin Use: AÂCase Report. Journal of Emergency Medicine, 2018, 54, 109-111.	0.7	24
277	Liver X receptor activation inhibits SGLT2â€mediated glucose transport in human renal proximal tubular cells. Experimental Physiology, 2018, 103, 250-260.	2.0	3
278	Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease. Journal of Korean Diabetes, 2018, 19, 88.	0.3	1
279	New Tubulocentric Insights for Diabetic Nephropathy: From Pathophysiology to Treatment. , 0, , .		1
280	SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?. Diabetes Care, 2018, 41, 2444-2447.	8.6	14
281	Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. Mayo Clinic Proceedings, 2018, 93, 1629-1647.	3.0	31
282	Synthetic and Biological Studies of Carbasugar SGLT2 Inhibitors. Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 2018, 76, 1215-1222.	0.1	4

ARTICLE IF CITATIONS Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk 283 0.5 7 patients with diabetes mellitus. Indian Heart Journal, 2018, 70, 915-921. Comparative high-performance liquid chromatographic and high-performance thin-layer chromatographic study for the simultaneous determination of dapagliflozin and metformin hydrochloride in bulk and pharmaceutical formulation. Journal of Planar Chromatography - Modern 284 1.2 9 TĹC, 2018, 31, 469-476. MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer. 285 7 3.3 International Journal of Oncology, 2018, 54, 199-208. Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease. Open Medicine (Poland), 286 1.3 2018, 13, 402-409. 12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. 287 A randomized clinical trial in the elderly with Type-2 diabetes mellitus. Clinical Pharmacology: 1.2 17 Advances and Applications, 2018, Volume 10, 141-151. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care, 2018, 41, 2552-2559. 288 8.6 The Role of Bridging Water and Hydrogen Bonding as Key Determinants of Noncovalent 289 3.2 6 Proteinâ€"Carbohydrate Recognition. ChemMedChem, 2018, 13, 2684-2693. Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose 5.6 reabsorption. Biomedicine and Pharmacotherapy, 2018, 108, 355-366. Design, synthesis and biological evaluation of 291 (2S, 3R, 4R, 5S, 6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3, 4-diols as potent and orally 2.2 9 active SGLT dual inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3446-3453. Synthesis and Pd-catalyzed coupling of1-<i>C</i>-stannylated glycals. Journal of Carbohydrate 1.1 Chemistry, 2018, 37, 347-369. Recent progress of sodium-glucose transporter 2 inhibitors as potential antidiabetic agents. Future 293 2.3 8 Medicinal Chemistry, 2018, 10, 1261-1276. Exploiting Synergistic Effects in Organozinc Chemistry for Direct Stereoselective Câ€Glycosylation 294 13.8 Reactions at Room Temperature. Angewandte Chemié - International Edition, 2018, 57, 10630-10634. Insulin dependent and independent normalization of blood glucose levels reduces the enhanced 295 rewarding effects of nicotine in a rodent model of diabetes. Behavioural Brain Research, 2018, 351, 2.2 11 75-82. Genomic integration of ERRÎ³-HNF1Î² regulates renal bioenergetics and prevents chronic kidney disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4910-E4919. 7.1 Nucleosome Positioning and Gene Regulation of the <i>SGLT2</i> Gene in the Renal Proximal Tubular 297 2.313 Epithelial Cells. Molecular Pharmacology, 2018, 94, 953-962. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of 298 sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. International Journal of Medical Sciences, 2018, 15, 937-943. Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional 299 constipation: a randomised, placebo-controlled, double-blind phase 2 trial. The Lancet 8.1 29 Gastroenterology and Hepatology, 2018, 3, 603-613. Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction 6.8 following experimental myocardial infarction. Cardiovascular Diabetology, 2018, 17, 99.

#	Article	IF	CITATIONS
301	Medicaid Eligibility Expansions May Address Gaps In Access To Diabetes Medications. Health Affairs, 2018, 37, 1200-1207.	5.2	23
302	Phlorizin Exerts Direct Protective Effects on Palmitic Acid (PA)-Induced Endothelial Dysfunction by Activating the PI3K/AKT/eNOS Signaling Pathway and Increasing the Levels of Nitric Oxide (NO). Medical Science Monitor Basic Research, 2018, 24, 1-9.	2.6	40
303	Secondary Prevention of Coronary Artery Disease. , 2018, , 479-487.		1
304	One-Pot Assembly of Unsymmetrical Biaryl Thioglycosides through Chemoselective Palladium-Catalyzed Three-Component Tandem Reaction. Organic Letters, 2018, 20, 4067-4071.	4.6	23
305	The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice. International Journal of Molecular Sciences, 2018, 19, 137.	4.1	64
306	Study Design Selection in Early Clinical Antiâ€Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 432-441.	2.5	5
307	Stereocontrolled Synthesis of 2-Deoxy- <i>C</i> -glycopyranosyl Arenes Using Glycals and Aromatic Amines. Organic Letters, 2018, 20, 3079-3082.	4.6	28
308	Ion-pair solid phase extraction for the simultaneous separation and quantitation of metformin and canagliflozin in human plasma by LC-MS/MS. Microchemical Journal, 2018, 143, 181-189.	4.5	18
309	Exploiting Synergistic Effects in Organozinc Chemistry for Direct Stereoselective C lycosylation Reactions at Room Temperature. Angewandte Chemie, 2018, 130, 10790-10794.	2.0	0
310	Efficacy and safety of ipragliflozin as an addâ€on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial. Diabetes, Obesity and Metabolism, 2018, 20, 2408-2415.	4.4	30
311	Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents. Bioorganic and Medicinal Chemistry, 2018, 26, 3947-3952.	3.0	11
312	Efficacy and safety of ipragliflozin as add-on to metformin for type 2 diabetes: a meta-analysis of double-blind randomized controlled trials. Postgraduate Medicine, 2019, 131, 578-588.	2.0	3
313	Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes. PLoS ONE, 2019, 14, e0220667.	2.5	12
314	Can Galactose Be Converted to Glucose in HepG2 Cells? Improving the <i>in Vitro</i> Mitochondrial Toxicity Assay for the Assessment of Drug Induced Liver Injury. Chemical Research in Toxicology, 2019, 32, 1528-1544.	3.3	11
315	The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection. Future Medicinal Chemistry, 2019, 11, 1285-1303.	2.3	15
316	The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update. Biomedicine and Pharmacotherapy, 2019, 120, 109526.	5.6	15
318	Drug Utilization Patterns in Patients with Diabetes Initiating Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Japan: A Multi-Database Study (2014–2017). Diabetes Therapy, 2019, 10, 2233-2249.	2.5	5
319	Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus. Diabetes Therapy, 2019, 10, 2219-2231.	2.5	5

	CITATIO	CITATION REPORT	
#	Article	IF	CITATIONS
320	Sigmoidal kinetics define porcine intestinal segregation of electrogenic monosaccharide transport systems as having multiple transporter population involvement. Physiological Reports, 2019, 7, e14090.	1.7	4
321	Dapagliflozin Prevents NOX- and SGLT2-Dependent Oxidative Stress in Lens Cells Exposed to Fructose-Induced Diabetes Mellitus. International Journal of Molecular Sciences, 2019, 20, 4357.	4.1	27
322	Glucose Metabolism in Pancreatic Cancer. Cancers, 2019, 11, 1460.	3.7	74
323	Acute and Direct Effects of Sodium–Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats. Biological and Pharmaceutical Bulletin, 2019, 42, 1707-1712.	1.4	4
324	Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1241-1250.	7.1	98
325	The impact of sugar consumption on stress driven, emotional and addictive behaviors. Neuroscience and Biobehavioral Reviews, 2019, 103, 178-199.	6.1	116
326	A novel SGLT2 inhibitor, SU-011, improves glycaemic control in rodents without the risk of hypoglycaemia and weight gain. Journal of Pharmacy and Pharmacology, 2019, 71, 1393-1399.	2.4	3
327	Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: Implications for lowering tissue damage. Life Sciences, 2019, 231, 116538.	4.3	17
328	Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors. Clinical Drug Investigation, 2019, 39, 683-690.	2.2	19
329	Promise, peril, and possible new treatment options incurred by sodium glucose co-transporter 2 (SGLT2) inhibitors: A precise review up to 2018. Obesity Medicine, 2019, 14, 100099.	0.9	0
330	Hydroxyl Groups in Synthetic and Natural-Product-Derived Therapeutics: A Perspective on a Common Functional Group. Journal of Medicinal Chemistry, 2019, 62, 8915-8930.	6.4	91
331	Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors. Diabetes and Metabolism Journal, 2019, 43, 158.	4.7	17
332	Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium–glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus. British Journal of Clinical Pharmacology, 2019, 85, 1808-1819	2.4	8
333	Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 1679-1683.	3.6	11
334	Pharmacologic treatment options for type 1 diabetes: what's new?. Expert Review of Clinical Pharmacology, 2019, 12, 471-479.	3.1	13
335	Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovascular Diabetology, 2019, 18, 20.	6.8	101
336	Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study. Diabetes Therapy, 2019, 10, 951-963.	2.5	21
337	The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury. Kidney and Blood Pressure Research, 2019, 44, 149-157.	2.0	37

#	Article	IF	CITATIONS
338	Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan. Diabetes Therapy, 2019, 10, 549-562.	2.5	10
339	Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes. Clinical Diabetes, 2019, 37, 211-220.	2.2	1
340	Evaluating All Potential Oral Complications of Diabetes Mellitus. Frontiers in Endocrinology, 2019, 10, 56.	3.5	155
341	Palladium-Catalyzed Stereospecific <i>C</i> -Glycosylation of Glycals with Vinylogous Acceptors. ACS Catalysis, 2019, 9, 2909-2915.	11.2	36
342	Antioxidative potential of antidiabetic agents: A possible protective mechanism against vascular complications in diabetic patients. Journal of Cellular Physiology, 2019, 234, 2436-2446.	4.1	71
343	Fighting Type-2 Diabetes: Present and Future Perspectives. Current Medicinal Chemistry, 2019, 26, 1891-1907.	2.4	13
344	Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. American Journal of Transplantation, 2019, 19, 907-919.	4.7	82
345	Intestinal electrogenic sodium-dependent glucose absorption in tilapia and trout reveal species differences in <i>SLC5A</i> -associated kinetic segmental segregation. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2019, 316, R222-R234.	1.8	12
346	Effect of sodiumâ€glucose cotransporter 2 inhibitor, empagliflozin, and αâ€glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes. Journal of Cellular Biochemistry, 2019, 120, 8534-8546.	2.6	34
347	Sodium–glucose cotransporter inhibitors and oxidative stress: An update. Journal of Cellular Physiology, 2019, 234, 3231-3237.	4.1	99
348	Firstâ€dose effect of the <scp>SGLT</scp> 2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 266-273.	1.9	3
349	Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 876-882.	4.4	18
350	SGLT1 inhibition boon or bane for diabetesâ€associated cardiomyopathy. Fundamental and Clinical Pharmacology, 2020, 34, 173-188.	1.9	12
351	Palladium atalysed C(sp ³)â^H Glycosylation for the Synthesis of Câ€Alkyl Glycoamino Acids. Angewandte Chemie, 2020, 132, 3519-3522.	2.0	30
352	The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis. Endocrine, 2020, 67, 294-304.	2.3	23
353	A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study. Mayo Clinic Proceedings, 2020, 95, 90-100.	3.0	30
354	Insights on the current status and advancement of diabetes mellitus type 2 and to avert complications: An overview. Biotechnology and Applied Biochemistry, 2020, 67, 920-928.	3.1	14
355	The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis. CardioRenal Medicine, 2020, 10, 1-10.	1.9	80

#	Article	IF	CITATIONS
356	SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function. Frontiers in Cardiovascular Medicine, 2019, 6, 186.	2.4	71
357	Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review. Life Sciences, 2020, 240, 117090.	4.3	54
358	Palladium atalysed C(sp ³)â^'H Glycosylation for the Synthesis of Câ€Alkyl Glycoamino Acids. Angewandte Chemie - International Edition, 2020, 59, 3491-3494.	13.8	48
359	Optimization of Culture Conditions for the Efficient Biosynthesis of Trilobatin from Phloretin by Engineered <i>Escherichia coli</i> Harboring the Apple Phloretin-4′- <i>O</i> -glycosyltransferase. Journal of Agricultural and Food Chemistry, 2020, 68, 14212-14220.	5.2	5
360	Efficacy and Safety of SGLT-2 Inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis. Medical Sciences (Basel, Switzerland), 2020, 8, 47.	2.9	24
361	Phlorizin ameliorates obesity-associated endotoxemia and insulin resistance in high-fat diet-fed mice by targeting the gut microbiota and intestinal barrier integrity. Gut Microbes, 2020, 12, 1842990.	9.8	117
362	Bioactive C-glycosides inspired from natural products towards therapeutics. , 2020, , 97-153.		5
363	The effects of ertugliflozin on βâ€cell function: Pooled analysis from four phase 3 randomized controlled studies. Diabetes, Obesity and Metabolism, 2020, 22, 2267-2275.	4.4	2
364	Diabetes, and its treatment, as an effector of autonomic nervous system circuits and its functions. Current Opinion in Pharmacology, 2020, 54, 18-26.	3.5	2
365	Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1154, 122281.	2.3	11
366	Prolonged euglycemic diabetic ketoacidosis triggered by a single dose of sodium–glucose cotransporter 2 inhibitor. BMJ Case Reports, 2020, 13, e235969.	0.5	5
367	Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 2823-2831.	2.4	10
368	SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease. Journal of Clinical Medicine, 2020, 9, 2723.	2.4	13
369	Development of Routes for the Stereoselective Preparation of β-Aryl- <i>C</i> -glycosides via <i>C</i> -1 Aryl Enones. Organic Letters, 2020, 22, 7650-7655.	4.6	18
370	Syntheses of SGLT2 Inhibitors by Ni- and Pd-Catalyzed Fukuyama Coupling Reactions. Journal of Organic Chemistry, 2020, 85, 12382-12392.	3.2	6
371	Cardioprotective effects of short-term empagliflozin treatment in db/db mice. Scientific Reports, 2020, 10, 19686.	3.3	13
372	<p>SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy</p> . Drug Design, Development and Therapy, 2020, Volume 14, 4775-4788.	4.3	32
373	Treating neutropenia and neutrophil dysfunction in glycogen storage disease type lb with an SGLT2 inhibitor. Blood, 2020, 136, 1033-1043.	1.4	90

ARTICLE IF CITATIONS Adjunct therapies in treatment of type 1 diabetes. Journal of Diabetes, 2020, 12, 742-753. 374 1.8 17 Cancer Biology and Prevention in Diabetes. Cells, 2020, 9, 1380. 4.1 39 Discontinuation rate and reason for discontinuation after sodiumâ€glucose cotransporter 2 inhibitor 376 1.5 5 prescription in real clinical practice. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1271-1277. Pharmaceutical Analytical Profile for Novel SGL-2 Inhibitor: Dapagliflozin. Critical Reviews in Analytical Chemistry, 2021, 51, 1-13. Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 378 4.5 29 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin. Pharmaceutics, 2020, 12, 268. Synthesis of Benzyl <i>C</i>â€Analogues of Dapagliflozin as Potential SGLT2 Inhibitors. European Journal of Organic Chemistry, 2020, 2020, 1828-1839. 379 2.4 Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice. Journal of 380 2.0 45 Atherosclerosis and Thrombosis, 2020, 27, 1141-1151. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic 3.5 67 apolipoprotein E-deficient mice. European Journal of Pharmacology, 2020, 875, 173040. A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after 382 2.6 21 gestational diabetes mellitus. American Journal of Obstetrics & amp; Gynecology MFM, 2020, 2, 100139. Cardiovascular Risks and Benefits of Medications Used for Weight Loss. Frontiers in Endocrinology, 3.5 2019, 10, 883. Canagliflozin impairs blood reperfusion of ischaemic lower limb partially by inhibiting the retention and paracrine function of bone marrow derived mesenchymal stem cells. ÉBioMedicine, 2020, 52, 384 12 6.1 102637. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). PLoS ONE, 2.5 2020, 15, e0232283. Effectiveness in the inhibition of dapagliflozin and canagliflozin on M-type K+ current and α-methylglucoside-induced current in pituitary tumor (ĞH3) and pheochromocytoma PC12 cells. European Journal of Pharmacology, 2020, 879, 173141. 386 3.5 4 Investigation and Management of Stool Frequency and Consistency Associated With SGLT1 Inhibition by Reducing Dietary Carbohydrate: A Randomized Trial. Clinical Pharmacology and Therapeutics, 2020, 108, 995-1002. C-Glycosylation enabled by N-(glycosyloxy)acetamides. Organic and Biomolecular Chemistry, 2020, 18, 388 2.8 12 3043-3046. An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option. Expert Opinion on Pharmacotherapy, 2020, 21, 1157-1166. 1.8 Metronidazole-conjugates: A comprehensive review of recent developments towards synthesis and 390 5.512 medicinal perspective. European Journal of Medicinal Chemistry, 2021, 210, 112994. The use of South African botanical species for the control of blood sugar. Journal of 4.1 Ethnopharmacology, 2021, 264, 113234.

#	Article	IF	CITATIONS
392	SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. Journal of Human Hypertension, 2021, 35, 12-25.	2.2	30
393	The impact of sodium glucose coâ€transporter 2 inhibitors on nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 893-909.	2.8	13
394	Palladiumâ€Catalyzed Regioselective and Diastereoselective C â€Glycosylation by Allylâ€Allyl Coupling. Advanced Synthesis and Catalysis, 2021, 363, 846-850.	4.3	7
395	Fibroblast growth factor 21: a novel long-acting hypoglycemic drug for canine diabetes. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 1031-1043.	3.0	1
396	Target Validation—Prosecuting the Target. , 2021, , .		0
397	Plant Alkaloids with Antidiabetic Potential. , 2021, , 251-266.		0
398	Flavonoids as potential agents in the management of type 2 diabetes through the modulation of α-amylase and α-glucosidase activity: a review. Critical Reviews in Food Science and Nutrition, 2022, 62, 3137-3207.	10.3	67
399	Mitochondrial Dysfunction and Heart Disease: Critical Appraisal of an Overlooked Association. International Journal of Molecular Sciences, 2021, 22, 614.	4.1	33
400	Synthesis of C- and S-Glycosides. , 2021, , 160-199.		1
401	SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study. Current Cardiology Reviews, 2021, 16, 258-265.	1.5	7
402	Potential mechanisms underlying the renoprotective effect of empagliflozin, a novel selective sodium glucose co-transporter (SGLT) 2 inhibitor, against diabetic nephropathy in streptozotocin induced diabetic rats. Bulletin of Egyptian Society for Physiological Sciences, 2021, .	0.2	1
403	Efficacy and safety of the SGLT2 inhibitor dapagliflozin in typeÂ1 diabetes: A metaâ€analysis of randomized controlled trials. Experimental and Therapeutic Medicine, 2021, 21, 382.	1.8	12
404	Efficacy and safety of combination therapy with sodium–glucose cotransporter 2 inhibitors and renin–angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2022, 37, 720-729.	0.7	17
405	Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway. Diabetes and Metabolism Journal, 2021, 45, 921-932.	4.7	21
406	Diastereoselective Synthesis of Aryl <i>C</i> â€Glycosides from Glycosyl Esters via Câ^'O Bond Homolysis. Angewandte Chemie - International Edition, 2021, 60, 9433-9438.	13.8	100
407	Phloridzin Acts as an Inhibitor of Protein-Tyrosine Phosphatase MEG2 Relevant to Insulin Resistance. Molecules, 2021, 26, 1612.	3.8	5
408	Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor. Bioorganic and Medicinal Chemistry, 2021, 34, 116033.	3.0	6
409	A case report of euglycemic ketoacidosis due to dapagliflozin treatment. Turkish Journal of Internal Medicine, 0, , .	0.6	0

		15	0
#	ARTICLE	IF	CITATIONS
410	A systematic review and dose-response meta-analysis on the efficacy of dapaglifiozin in patients with type 1 diabetes mellitus. Pharmacological Research, 2021, 165, 105456.	7.1	6
411	Diastereoselective Synthesis of Aryl <i>C</i> â€Glycosides from Glycosyl Esters via Câ^'O Bond Homolysis. Angewandte Chemie, 2021, 133, 9519-9524.	2.0	18
412	Network medicine framework shows that proximity of polyphenol targets and disease proteins predicts therapeutic effects of polyphenols. Nature Food, 2021, 2, 143-155.	14.0	57
413	Biocatalytic Application of a Membraneâ€Bound Coumarin Câ€Glucosyltransferase in the Synthesis of Coumarin and Benzofuran Câ€Glucosides. Advanced Synthesis and Catalysis, 2021, 363, 5072-5078.	4.3	6
414	Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?. Molecular Metabolism, 2021, 46, 101158.	6.5	17
415	Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin. Neoplasia, 2021, 23, 391-399.	5.3	18
416	Diabetes Mellitus: Insights from Epidemiology, Biochemistry, Risk Factors, Diagnosis, Complications and Comprehensive Management. International Journal of Diabetology, 2021, 2, 36-50.	2.0	67
418	Repurposing of Anti-Diabetic Agents as a New Opportunity to Alleviate Cognitive Impairment in Neurodegenerative and Neuropsychiatric Disorders. Frontiers in Pharmacology, 2021, 12, 667874.	3.5	17
419	A systematic review and meta-analysis of the impact of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiovascular outcomes in biologically healthy older adults. British Journal of Diabetes, 2021, 21, 30-35.	0.2	7
420	Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study. Diabetes and Metabolism Journal, 2021, 45, 339-348.	4.7	14
421	Chitosan Oligosaccharide Alleviates Abnormal Glucose Metabolism without Inhibition of Hepatic Lipid Accumulation in a High-Fat Diet/Streptozotocin-Induced Diabetic Rat Model. Marine Drugs, 2021, 19, 360.	4.6	10
422	Long-Term Impact of Diabetes Mellitus on Initially Conservatively Managed Patients With Severe Aortic Stenosis. Circulation Journal, 2021, 85, 1083-1092.	1.6	3
423	Impact of sodium glucose linked cotransporterâ€2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus. Physiological Reports, 2021, 9, e14890.	1.7	13
424	Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators. Journal of Clinical Medicine, 2021, 10, 2713.	2.4	5
425	Nucleophilic Ringâ€Opening of 1,6â€Anhydrosugars: Recent Advances and Applications in Organic Synthesis. European Journal of Organic Chemistry, 2021, 2021, 3501-3515.	2.4	5
426	Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2. Biochemical and Biophysical Research Communications, 2021, 557, 62-68.	2.1	10
427	Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis. Advanced Drug Delivery Reviews, 2021, 174, 127-139.	13.7	16
429	Sodium-glucose cotransporter 2 (SGLT-2) inhibition and kidney protection: Does improvement in kidney hypoxia play a role?. EClinicalMedicine, 2021, 37, 100983.	7.1	1

ARTICLE IF CITATIONS # Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic 431 3.3 40 review and meta-analysis. Scientific Reports, 2021, 11, 15364. SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report. Clinical 2.7 Diabetes and Endocrinology, 2021, 7, 17. Sodiumâ€glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac 433 3.111 function: systematic review. ESC Heart Failure, 2021, 8, 4093-4118. Cardioprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors Regardless of Type 2 Diabetes 434 0.1 Mellitus: A Meta-analysis. International Journal of Cardiovascular Sciences, 2021, , . Diabetic Kinome Inhibitorsâ€"A New Opportunity for Î²-Cells Restoration. International Journal of 435 4.1 9 Molecular Sciences, 2021, 22, 9083. Effects of Food on the Pharmacokinetic Properties and Mass Balance of Henagliflozin in Healthy Male Volunteers. Clinical Therapeutics, 2021, 43, e264-e273. 2.5 Bioactive Peptides as Potential Nutraceuticals for Diabetes Therapy: A Comprehensive Review. 437 4.1 35 International Journal of Molecular Sciences, 2021, 22, 9059. $\hat{a} \in \infty$ The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and 3.5 pharmacogenomics〕 European Journal of Pharmacology, 2021, 904, 174169. 440 Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function. Biomedicines, 2021, 9, 1356. 3.2 45 Cellular binding and uptake of fluorescent glucose analogs 2-NBDG and 6-NBDG occurs independent 441 2.6 of membrane glucose transporters. Biochimie, 2021, 190, 1-11. Application of carbohydrates in approved small molecule drugs: A review. European Journal of 442 5.526 Medicinal Chemistry, 2021, 223, 113633. Sodium/glucose cotransporter 2 and renoprotection: From the perspective of energy regulation and 2.5 water conservation. Journal of Pharmacological Sciences, 2021, 147, 245-250. Diabetes Mellitus: An Update. Current Cardiology Reviews, 2021, 16, 252-252. 444 1.5 0 Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic 445 2.8 steatosis in high-fat diet induced obese mice. Adipocyte, 2021, 10, 446-455. Mammalian Solute Carrier Families SLC2 and SLC5: Facilitative and Active Transport of Hexoses and 446 1 Polyols., 2018, , 627-651. Synthesis of Benzyl 2-Deoxy-<i>C</i>Glycosides. ACS Omega, 2020, 5, 33196-33205. 447 Regio- and diastereoselective Pd-catalyzed synthesis of C2-aryl glycosides. Chemical Communications, 448 4.1 10 2020, 56, 7175-7178. 449 Vacuolar Proton Pump (V-ATPase) and Insulin Secretion., 2014, , 171-188.

#	Article	IF	CITATIONS
450	Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models. PLoS ONE, 2012, 7, e30555.	2.5	193
451	Influence of Familial Renal Glycosuria Due to Mutations in the SLC5A2 Gene on Changes in Glucose Tolerance over Time. PLoS ONE, 2016, 11, e0146114.	2.5	22
452	The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS ONE, 2016, 11, e0146337.	2.5	135
453	Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS ONE, 2016, 11, e0151511.	2.5	191
454	Third Exposure to a Reduced Carbohydrate Meal Lowers Evening Postprandial Insulin and GIP Responses and HOMA-IR Estimate of Insulin Resistance. PLoS ONE, 2016, 11, e0165378.	2.5	9
455	Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes. PLoS ONE, 2016, 11, e0165703.	2.5	140
456	Ameliorative effect of polydatin on hyperglycemia and renal injury in streptozotocin-induced diabetic rats. Cellular and Molecular Biology, 2019, 65, 55-59.	0.9	7
457	Targeting beta-cell preservation in the management of type 2 diabetes. British Journal of Diabetes, 2017, 17, 134-144.	0.2	13
459	Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease. EXCLI Journal, 2015, 14, 684-96.	0.7	20
460	Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice. Oncotarget, 2017, 8, 58353-58363.	1.8	47
461	The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia. Current Medicinal Chemistry, 2020, 27, 6682-6702.	2.4	16
462	Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Current Topics in Medicinal Chemistry, 2019, 19, 1818-1849.	2.1	22
463	Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry. Medicinal Chemistry, 2015, 11, 317-328.	1.5	27
464	Lead Optimization Resources in Drug Discovery for Diabetes. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2019, 19, 754-774.	1.2	6
465	A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 328-334.	1.2	20
466	Reduction in the Amplitude of Shortening and Ca2+ Transient by Phlorizin and Quercetin-3-O-Glucoside in Ventricular Myocytes From Streptozotocin-Induced Diabetic Rats. Physiological Research, 2016, 65, 239-250.	0.9	3
467	Anti-diabetic activities of Dactylorhiza hatagirea leaf extract in 3T3-L1 cell line model. Pharmacognosy Magazine, 2019, 15, 212.	0.6	9
468	Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. International Journal of Clinical Pharmacology and Therapeutics, 2015, 53, 115-128.	0.6	34

#	Article	IF	CITATIONS
469	Development and Recent Advancement of SGLT2 Inhibitors for the Treatment Regime of T2DM. Journal of Biomedicine, 2016, 1, .	0.0	2
470	Benefits and harms of sodiumâ€glucose coâ€transporterâ€2 inhibitors (SCLT2â€I) and renin–angiotensin–aldosterone system inhibitors (RAASâ€I) versus SCLT2â€Is alone in patients with type 2 diabetes: A systematic review and metaâ€analysis of randomized controlled trials. Endocrinology, Diabetes and Metabolism, 2022. 5, e00303.	2.4	12
471	Dapagliflozin Reduces Urinary Albumin Excretion by Downregulating the Expression of cAMP, MAPK, and cGMP-PKG Signaling Pathways Associated Genes. Genetic Testing and Molecular Biomarkers, 2021, 25, 627-637.	0.7	2
473	The Mammalian Solute Carrier Families SLC2 and SLC5: Facilitative and Active Transport of Hexoses and Polyols. , 2014, , 1-27.		0
474	The recent advances in therapy for diabetes mellitus. The Journal of Japanese Society of Limb Salvage and Podiatric Medicine, 2014, 6, 21-32.	0.0	0
475	SGLT2 Inhibitors for Treating Diabetes. , 2017, , 13-35.		0
476	Comparison of Diuretic Effects between Empagliflozin, a Sodium-Clucose Co-Transporter 2 Inhibitor With Osmotic Diuresis, and Tolvaptan, a Water Diuretic, in Two Type 2 Diabetic Patients Taking Sodium Diuretics. Sports and Exercise Medicine - Open Journal, 2016, 2, 45-49.	0.3	1
477	Sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: insights from the CVD-REAL study. Annals of Translational Medicine, 2018, 6, 55-55.	1.7	3
479	Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life. Current Diabetes Reviews, 2020, 16, 716-732.	1.3	0
480	Protective effects of phloretin and phloridzin on indomethacin-induced gastric ulcers in mice: characterization of potential molecular mechanisms. Cukurova Medical Journal, 2020, 45, 1459-1466.	0.2	2
481	SGLT2 Inhibitors: A Noval Therapuetic Agent in the Treatment of Diabetic Kidney Disease. Journal of Drug Delivery and Therapeutics, 2020, 10, 203-206.	0.5	0
482	Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview. P and T, 2015, 40, 451-62.	0.9	43
483	Glucose Metabolism in Acute Kidney Injury and Kidney Repair. Frontiers in Medicine, 2021, 8, 744122.	2.6	22
484	Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China. Frontiers in Pharmacology, 2021, 12, 733681.	3.5	22
485	Quantifying the relationship between dapagliflozin and loss of weight in type 1 diabetes mellitus patients. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 237-242.	1.5	4
486	Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease—Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors. Antioxidants, 2021, 10, 1935.	5.1	15
487	Advances in Pd-catalyzed Câ \in C bond formation in carbohydrates and their applications in the synthesis of natural products and medicinally relevant molecules. RSC Advances, 2021, 11, 34369-34391.	3.6	14
488	Naturally Occurring SGLT2 Inhibitors: A Review. Advances in Experimental Medicine and Biology, 2021, 1328, 523-530.	1.6	1

#	Article	IF	CITATIONS
489	Adherence and persistence rates of major antidiabetic medications: a review. Diabetology and Metabolic Syndrome, 2022, 14, 12.	2.7	24
490	Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. Pharmacological Research, 2022, 175, 106039.	7.1	26
491	Recent advances in palladium-catalyzed C(sp ³)/C(sp ²)–H bond functionalizations: access to C-branched glycosides. Organic and Biomolecular Chemistry, 2022, 20, 264-281.	2.8	19
492	Natural bio functional lipids containing solid self-microemulsifying drug delivery system of Canagliflozin for synergistic prevention of type 2 diabetes mellitus. Journal of Drug Delivery Science and Technology, 2022, 69, 103138.	3.0	4
493	Sex-Specific Computational Models of Kidney Function in Patients With Diabetes. Frontiers in Physiology, 2022, 13, 741121.	2.8	11
494	Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD. Pediatric Nephrology, 2022, , 1.	1.7	1
495	Dapagliflozin diminishes memory and cognition impairment in Streptozotocin induced diabetes through its effect on Wnt/β-Catenin and CREB pathway. Brain Research Bulletin, 2022, 181, 109-120.	3.0	4
496	Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium–Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus. Pharmaceuticals, 2022, 15, 203.	3.8	0
497	Effects of Sodium-Glucose Cotransporter 2 on Amputation Events: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials. Pharmacology, 2022, 107, 123-130.	2.2	9
498	Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model. PLoS ONE, 2022, 17, e0261310.	2.5	6
499	Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review. Clinical and Molecular Hepatology, 2022, 28, 725-738.	8.9	10
500	Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition. Current Hypertension Reports, 2022, 24, 67-74.	3.5	11
501	Palladium atalyzed Reaction of Aryl Iodides and Glycal Enones: Application in the Preparation of Dapagliflozin Analogues. European Journal of Organic Chemistry, 2022, 2022, .	2.4	3
502	Intramuscular injection of sotagliflozin promotes neovascularization in diabetic mice through enhancing skeletal muscle cells paracrine function. Acta Pharmacologica Sinica, 2022, 43, 2636-2650.	6.1	5
503	Mode of Action and Human Relevance Assessment of Male CDâ€1 Mouse Renal Adenocarcinoma Associated With Lifetime Exposure to Empagliflozin. Journal of Applied Toxicology, 2022, , .	2.8	0
504	Anti-respiratory syncytial virus and anti-herpes simplex virus activity of six Tanzanian medicinal plants with extended studies of Erythrina abyssinica stem bark. Journal of Ethnopharmacology, 2022, 292, 115204.	4.1	4
506	Successful use of empagliflozin to treat neutropenia in two <scp>G6PC3</scp> â€deficient children: Impact of a mutation in <scp>SGLT5</scp> . Journal of Inherited Metabolic Disease, 2022, 45, 759-768.	3.6	17
507	Carbohydrate-based drugs launched during 2000â^'2021. Acta Pharmaceutica Sinica B, 2022, 12, 3783-3821.	12.0	68

#	Article	IF	CITATIONS
508	Structural mechanism of a dual-functional enzyme DgpA/B/C as both a C-glycoside cleaving enzyme and an O- to C-glycoside isomerase. Acta Pharmaceutica Sinica B, 2023, 13, 246-255.	12.0	7
509	Hypoglycemic natural products with in vivo activities and their mechanisms: a review. Food Science and Human Wellness, 2022, 11, 1087-1100.	4.9	15
510	Pharmacokinetics and Tissue Distribution of Enavogliflozin in Mice and Rats. Pharmaceutics, 2022, 14, 1210.	4.5	8
511	Structural Characteristics, Antioxidant and Hypoglycemic Activities of Polysaccharide from Siraitia grosvenorii. Molecules, 2022, 27, 4192.	3.8	17
512	Blocking of SGLT2 to Eliminate NADPH-Induced Oxidative Stress in Lenses of Animals with Fructose-Induced Diabetes Mellitus. International Journal of Molecular Sciences, 2022, 23, 7142.	4.1	8
513	Ruthenium atalyzed Stereo―and Site‧elective <i>orthoâ€</i> and <i>meta</i> â^'H Glycosylation and Mechanistic Studies. Angewandte Chemie - International Edition, 2022, 61, .	13.8	27
514	Empagliflozin modulates CD4 ⁺ Tâ€cell differentiation via metabolic reprogramming in immune thrombocytopenia. British Journal of Haematology, 2022, 198, 765-775.	2.5	4
515	Rutheniumâ€Catalyzed Stereo―and Siteâ€Selective <i>orthoâ€</i> and <i>meta</i> â€Câ^'H Glycosylation and Mechanistic Studies. Angewandte Chemie, 0, , .	2.0	5
516	Dapagliflozin Prevents Kidney Glycogen Accumulation and Improves Renal Proximal Tubule Cell Functions in a Mouse Model of Glycogen Storage Disease Type 1b. Journal of the American Society of Nephrology: JASN, 2022, 33, 1864-1875.	6.1	5
517	Sodiumâ€glucose coâ€transporter 2 inhibitors and hematopoiesis. Journal of Cellular Physiology, 2022, 237, 3778-3787.	4.1	6
518	Decursinol chloroacrylates useful as fungicides. Applied Biological Chemistry, 2022, 65, .	1.9	2
519	Sodiumâ€glucose cotransporterâ€2 inhibitorâ€induced euglycemic diabetic ketoacidosis: A case report. Journal of Clinical Pharmacy and Therapeutics, 0, , .	1.5	1
520	Effective Perturbations by Small-Molecule Modulators on Voltage-Dependent Hysteresis of Transmembrane Ionic Currents. International Journal of Molecular Sciences, 2022, 23, 9453.	4.1	5
521	Copper(I)-Catalyzed Sandmeyer-Type <i>S</i> -Arylation of 1-Thiosugars with Aryldiazonium Salts under Mild Conditions. Journal of Organic Chemistry, 2022, 87, 11414-11432.	3.2	6
522	A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present. European Journal of Medicinal Chemistry Reports, 2022, 6, 100074.	1.4	0
523	Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	6
524	Chapter 3. Optimizing the Current Type 2 Diabetes Antidiabetics with Nanotechnologies: Where Do We Stand?. RSC Nanoscience and Nanotechnology, 2022, , 92-112.	0.2	0
525	Weight Loss Effect of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients with Obesity without Diabetes: a Systematic Review. Acta Endocrinologica, 2022, 18, 216-224.	0.3	4

#	Article	IF	CITATIONS
526	Palladium cata-lyzed decarbox-ylative ï¢-C-glycosylation of glycals with ox-azol-5-(4H)-ones as acceptors. Organic Chemistry Frontiers, 0, , .	4.5	5
527	Mechanistic insights into the primary and secondary alterations of renal ion and water transport in the distal nephron. Journal of Internal Medicine, 2023, 293, 4-22.	6.0	11
528	Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. Diabetes Care, 2022, 45, 2907-2917.	8.6	6
529	Benefits of Taking Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: A Systematic Review. Cureus, 2022, , .	0.5	0
530	Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors. Minerva Endocrinology, 2022, 47, .	1.1	1
531	New insights into cellular links between sodium–glucose cotransporterâ€2 inhibitors and ketogenesis. Journal of Cellular Biochemistry, 2022, 123, 1879-1890.	2.6	2
532	Postâ€Modification of Amino Acids and Peptides for the Rapid Synthesis of <i>C</i> â€Glycoamino Acids and <i>C</i> â€Glycopeptides. European Journal of Organic Chemistry, 2022, 2022, .	2.4	4
533	Advances in the Synthesis of Natural Products and Medicinally Relevant Molecules from Glycals. ChemistrySelect, 2022, 7, .	1.5	3
534	Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder. Molecules, 2022, 27, 7174.	3.8	6
535	Emerging roles of sodiumâ€glucose coâ€ŧransporter inhibitors. The Prescriber, 2022, 33, 11-17.	0.3	0
536	Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China. Frontiers in Pharmacology, 0, 13, .	3.5	9
537	Sodium-Glucose Co-Transporter-2 Inhibitors and Epicardial Adiposity. European Journal of Pharmaceutical Sciences, 2022, , 106322.	4.0	5
539	Editorial: Regulation of lipid metabolism in adipose tissue and skeletal muscle. Frontiers in Physiology, 0, 13, .	2.8	0
540	SGLT2 inhibitors in type 2 diabetes: time to flozinate?. Practice Nursing, 2022, 33, 452-457.	0.1	0
541	Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu. Journal of Clinical Medicine, 2022, 11, 6544.	2.4	13
542	SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives. Cancers, 2022, 14, 5811.	3.7	24
543	Sodium-glucose transporter (SGLT2) inhibition: A potential target for treatment of type-2 Diabetes Mellitus with Natural and Synthetic compounds. Egyptian Journal of Basic and Applied Sciences, 2023, 10, 69-82.	0.6	0
544	Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin. EBioMedicine, 2022, 86, 104342.	6.1	2

#	Article	IF	CITATIONS
545	Examination of the emerging role of transporters in the assessment of nephrotoxicity. Expert Opinion on Drug Metabolism and Toxicology, 0, , 1-18.	3.3	0
546	Canagliflozin promotes osteoblastic MC3T3-E1 differentiation via AMPK/RUNX2 and improves bone microarchitecture in type 2 diabetic mice. Frontiers in Endocrinology, 0, 13, .	3.5	2
548	Nutritional and functional profile of carob bean (<i>Ceratonia siliqua</i>): a comprehensive review. International Journal of Food Properties, 2023, 26, 389-413.	3.0	8
549	Direct synthesis of unprotected aryl C-glycosides by photoredox Ni-catalysed cross-coupling. , 2023, 2, 251-260.		10
550	Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	11
551	Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor. Scientific Reports, 2023, 13, .	3.3	3
552	SGLT2 inhibitors and autophagy in diabetes. Cell Biochemistry and Function, 2023, 41, 392-398.	2.9	2
553	Combined treatment with teneligliptin and canagliflozin additively suppresses high-fat diet-induced body weight gain in mice with modulation of lipid metabolism-related gene expression. European Journal of Pharmacology, 2023, 947, 175682.	3.5	0
554	Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models. Biomedicine and Pharmacotherapy, 2023, 161, 114445.	5.6	3
555	Alleviating effects and mechanisms of action of large-leaf yellow tea drinking on diabetes and diabetic nephropathy in mice. Food Science and Human Wellness, 2023, 12, 1660-1673.	4.9	7
556	Cognitive benefits of Sodium-Glucose Co-Transporters-2 Inhibitors in the Diabetic Milieu. Current Medicinal Chemistry, 2023, 30, .	2.4	1
557	Novel targets for potential therapeutic use in Diabetes mellitus. Diabetology and Metabolic Syndrome, 2023, 15, .	2.7	10
558	Directed Palladiumâ€Catalyzed <i>pseudo</i> â€Anomeric Câ^'H Functionalization of Glycalâ€Type Substrates: Access to Unsymmetrical <i>gem</i> â€Diarylmethyl <i>C</i> â€Glycosides. Advanced Synthesis and Catalysis, 2023, 365, 820-825.	4.3	4
559	A Diversifiable Synthetic Platform for the Discovery of New Carbasugar SGLT2 Inhibitors Using Azide–Alkyne Click Chemistry. Chemical and Pharmaceutical Bulletin, 2023, 71, 240-249.	1.3	0
560	Molecular and neural roles of sodium-glucose cotransporter 2 inhibitors in alleviating neurocognitive impairment in diabetic mice. Psychopharmacology, 2023, 240, 983-1000.	3.1	4
561	Stereoselective <i>C</i> â€Aryl Glycosylation by Catalytic Crossâ€Coupling of Heteroaryl Glycosyl Sulfones. Angewandte Chemie, 2023, 135, .	2.0	Ο
562	Stereoselective <i>C</i> â€Aryl Glycosylation by Catalytic Crossâ€Coupling of Heteroaryl Glycosyl Sulfones. Angewandte Chemie - International Edition, 2023, 62, .	13.8	15
563	A highly efficient and facile one pot synthesis of novel 1-glycopyranosyl-4-biaryl butenone derivatives. Synthetic Communications, 2023, 53, 640-647.	2.1	0

#	Article	IF	CITATIONS
564	Synthesis of SGLT-2 Inhibitors. , 2022, , .		0
565	Reversible-Hydrogen-Transfer-Mediated Anomerization of Azaheterocyclyl 2-Deoxy- <i>C</i> -glycosides and Mechanistic Studies. ACS Catalysis, 2023, 13, 5656-5664.	11.2	6
566	The relationship between CD4+ T cell glycolysis and their functions. Trends in Endocrinology and Metabolism, 2023, 34, 345-360.	7.1	4
568	Current understanding on pathogenesis and effective treatment of glycogen storage disease type lb with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders. Frontiers in Endocrinology, 0, 14, .	3.5	4
569	Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction. Experimental and Molecular Medicine, 2023, 55, 1174-1181.	7.7	2
570	Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass. Diabetes Technology and Therapeutics, 2023, 25, 467-475.	4.4	1
571	Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway. Biomedicine and Pharmacotherapy, 2023, 164, 114907.	5.6	4
572	Recent advances on synthesis of C-glycosides. Carbohydrate Research, 2023, 530, 108856.	2.3	5
573	Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors—is hemodynamics the key point?. American Journal of Physiology - Cell Physiology, 2023, 325, C243-C256.	4.6	2
574	Natural products from plants targeting key enzymes for the future development of antidiabetic agents. Natural Product Reports, 2023, 40, 1198-1249.	10.3	4
575	C–H Glycosylation of Native Carboxylic Acids: Discovery of Antidiabetic SGLT-2 Inhibitors. ACS Central Science, 2023, 9, 1129-1139.	11.3	5
576	Antioxidant, antihyperglycemic, and antihyperlipidemic properties of Chimonanthus salicifolius S. Y. Hu leaves in experimental animals: modulation of thioredoxin and glutathione systems, renal water reabsorption, and gut microbiota. Frontiers in Nutrition, 0, 10, .	3.7	0
577	Therapeutic potential of multifunctional myricetin for treatment of type 2 diabetes mellitus. Frontiers in Nutrition, 0, 10, .	3.7	4
579	Contemporary trends in the utilization of secondâ€line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes, Obesity and Metabolism, 2023, 25, 2980-2988.	4.4	3
580	Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes. European Journal of Gastroenterology and Hepatology, 0, , .	1.6	1
581	A pharmacokinetic study to correlate the hypoglycemic effect of phlorizin in rats: Identification of metabolites as inhibitors of sodium/glucose cotransporters. Journal of Mass Spectrometry, 2023, 58, .	1.6	0
582	Renal, cardiovascular, and safety outcomes of adding sodium–glucose cotransporter-2 inhibitors to insulin therapy in patients with type-2 diabetes: a meta-analysis. International Urology and Nephrology, 0, , .	1.4	0
583	Cellular mechanism of diabetes remission by bariatric surgery. Trends in Endocrinology and Metabolism, 2023, 34, 590-600.	7.1	1

#	Article	IF	CITATIONS
584	Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in nonâ€small cell lung cancer (NSCLC) through inhibition of HIFâ€1α. Molecular Oncology, 2023, 17, 2235-2256.	4.6	2
585	Antianginal effects of empagliflozin in patients with type 2 diabetesÂand refractory angina; a randomized, doubleâ€blind placeboâ€controlled trial (EMPTâ€ANGINA Trial). Clinical Cardiology, 2024, 47, .	1.8	0
586	Glycosylation of polyphenolic compounds: Design of a self-sufficient biocatalyst by co-immobilization of a glycosyltransferase, a sucrose synthase and the cofactor UDP. International Journal of Biological Macromolecules, 2023, 250, 126009.	7.5	1
587	Exploring Carob (Ceratonia siliqua L.): A Comprehensive Assessment of Its Characteristics, Ethnomedicinal Uses, Phytochemical Aspects, and Pharmacological Activities. Plants, 2023, 12, 3303.	3.5	ο
588	Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials. Journal of Diabetes and Its Complications, 2023, 37, 108558.	2.3	5
589	Nanoparticles with SGLT2 inhibitory activity: Possible benefits and future. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2023, 17, 102869.	3.6	Ο
590	Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus. Acta Pharmaceutica Sinica B, 2023, , .	12.0	0
591	The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status. International Journal of Molecular Sciences, 2023, 24, 14243.	4.1	1
593	DBS are suitable for 1,5-anhydroglucitol monitoring in GSD1b and G6PC3-deficient patients taking SGLT2 inhibitors to treat neutropenia. Molecular Genetics and Metabolism, 2023, 140, 107712.	1.1	1
594	Differential impact of glomerular and tubule-interstitial histological changes on kidney outcome between non-proteinuric and proteinuric diabetic nephropathy. Clinical and Experimental Nephrology, 0, , .	1.6	0
595	Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis. Heart Failure Reviews, 2024, 29, 207-217.	3.9	0
596	A Comparison of Efficacy among Syrian diabetic patients treated with Empagliflozin versus Dapagliflozin, a Randomized, Triple-blind, Two-period crossover study. Research Journal of Pharmacy and Technology, 2023, , 4642-4648.	0.8	Ο
597	Effects of dapagliflozin monotherapy and combined aerobic exercise on skeletal muscle mitochondrial quality control and insulin resistance in type 2 diabetes mellitus rats. Biomedicine and Pharmacotherapy, 2023, 169, 115852.	5.6	0
598	Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors. European Heart Journal - Cardiovascular Pharmacotherapy, 0, , .	3.0	0
599	Der Stoff aus der Apfelrinde im Kampf gegen Diabetes (Gliflozine). , 2023, , 79-91.		0
600	Glycogen storage disease type Ib: modern understanding of the pathogenesis of neutropenia and prospects for its treatment with empagliflozin. PediatriÄeskaÄ¢ FarmakologiÄ¢, 2023, 20, 498-506.	0.4	0
601	A Rare Case of Sodium-Glucose Cotransporter-2 Inhibitor-Induced Acute Pancreatitis. Cureus, 2023, , .	0.5	0
602	Recent Advances in the Synthesis of C-Glycosides from 1,2-Glycals Synthesis, 0, , .	2.3	0

#	Article	IF	CITATIONS
603	Synthesis, crystal structure, DFT calculation and confirmation of absolute configuration of empagliflozin. Journal of Molecular Structure, 2024, 1301, 137331.	3.6	0
604	SGLT2 Inhibitor Canagliflozin Alleviates High Glucose-Induced Inflammatory Toxicity in BV-2 Microglia. Biomedicines, 2024, 12, 36.	3.2	Ο
605	The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment Paradigm of CKD in Africa: An African Association of Nephrology Panel Position Paper. Kidney International Reports, 2024, 9, 526-548.	0.8	1
606	The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats. Fundamental and Clinical Pharmacology, 0, , .	1.9	0
607	Sodium-Glucose Cotransporter-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a Type 2 Diabetic Patient. Cureus, 2023, , .	0.5	0
608	On the origin of the electronic and magnetic circular dichroism of naphthyl C-glycosides: Anomeric configuration. Carbohydrate Research, 2023, , 109021.	2.3	0
609	Specialized metabolites degradation by microorganisms. Bioscience, Biotechnology and Biochemistry, 2024, 88, 270-275.	1.3	0
610	Investigation of co-treatment multi-targeting approaches in breast cancer cell lines. European Journal of Pharmacology, 2024, 966, 176328.	3.5	0
611	SGLT2 inhibition promotes glomerular repopulation by cells of renin lineage in experimental kidney disease. Acta Physiologica, 2024, 240, .	3.8	0
612	Maternal Phlorizin Intake Protects Offspring from Maternal Obesity-Induced Metabolic Disorders in Mice via Targeting Gut Microbiota to Activate the SCFA-GPR43 Pathway. Journal of Agricultural and Food Chemistry, 2024, 72, 4703-4725.	5.2	0
613	Hypoglycemic effects and associated mechanisms of resveratrol and related stilbenes in diet. Food and Function, 2024, 15, 2381-2405.	4.6	0
614	Flow Chemistry for Synthesis of 2-(C-Glycosyl)acetates from Pyranoses via Tandem Wittig and Michael Reactions. Organic Process Research and Development, 0, , .	2.7	0
615	Phytochemical Screening, <i>In Silico</i> Molecular Docking, ADME Properties, and <i>In Vitro</i> Antioxidant, Anticancer, and Antidiabetic Activity of Marine Halophyte <i>Suaeda maritima</i> (L.) Dumort. ACS Omega, 2024, 9, 11200-11216.	3.5	0
616	Non-insulin Medications for the Management of Type 2 Diabetes. Home Healthcare Now, 2024, 42, 72-77.	0.2	0
617	Effect of Sodium-Glucose Cotransporter 2 Inhibitors on the 24-Hour Ambulatory Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension: An Updated Meta-Analysis. Endocrine Practice, 2024, 30, 481-489.	2.1	0